Allen Kaplan to Child
This is a "connection" page, showing publications Allen Kaplan has written about Child.
Connection Strength
0.234
-
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018 04; 78(4):793-795.
Score: 0.067
-
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul; 132(1):101-9.
Score: 0.050
-
Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005 Jun; 94(6):662-9.
Score: 0.028
-
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 07; 77(7):1961-1990.
Score: 0.023
-
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018 03; 141(3):1138-1139.e7.
Score: 0.017
-
Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1715-1721.
Score: 0.016
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
Score: 0.012
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
Score: 0.011
-
Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. J Allergy Clin Immunol. 1981 Dec; 68(6):438-41.
Score: 0.006
-
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999 Nov; 104(5):1071-8.
Score: 0.005